J&J Unit Janssen Announced: Phase 3 Mariposa Study Met Primary Endpoint; Planned Interim Overall Survival Analysis Showed A Trend Favoring Combination Of Rybrevant And Lazertinib Compared To Osimertinib
Portfolio Pulse from Charles Gross
Johnson & Johnson's unit, Janssen Pharmaceutical, announced positive topline results from the Phase 3 MARIPOSA study. The study evaluated the combination of RYBREVANT and lazertinib versus osimertinib as a first-line treatment in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer. The study met its primary endpoint and showed a trend favoring the combination of RYBREVANT and lazertinib.
September 28, 2023 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Janssen unit announced positive results from a Phase 3 study, potentially boosting the company's pharmaceutical portfolio.
Positive clinical trial results often lead to increased investor confidence and can potentially boost a company's stock price. The successful Phase 3 trial of RYBREVANT and lazertinib could enhance J&J's pharmaceutical offerings and potentially increase its market share in the treatment of non-small cell lung cancer.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100